EXHIBIT 170

Feniger, Angela From:

Sent: Thursday, June 21, 2012 8:39 PM

To: Lipari, Patricia

Cc: Poshni, Faiza; Cosentino, Lisa

Subject: Suspicous Order Monitoring (SOM)

SO002.pdf Attachments:

Hi Patricia,

Can you please review question number of one of this SOP. There is no mention of "Par ships control substances on Friday", therefore can you please revaluated it and submit the appropriate update to Lisa.

Thank you.

Angela Feniger | Associate Director, Tech Writing & Documentation

Par Pharmaceutical Companies, Inc. | 2 Ram Ridge Road | Spring Valley, NY 10977 Phone: | angela.feniger@parpharm.com

www.parpharm.com



PAR PHARMAGEUTICAL INC. STANDARD OPERATING PROCEDURE

Title: SUSPIC	IOUS ORD	ER MONITORING (SOM)		
Department: SALES OPERATIONS		S.O.P. No.: S0002.0		
Supersedes: NA		Effective Date APR 1 7-2	Page 1 of 4	
Written by:	Signature: Vittica (1) 2a -			
	Print Na	me & Tille: PATRICIA d.	HAMI DIRECTOR COLECOKS	
	Date: 04-17-2012-			
Checked by:	Signature / #			
	Print Name & Title 1 1964 Port Dir Tech Uniter Designation			
	Date	04/17/2012		
Approved by:	Signature:			
	Print Name & Title 2 Son Star Solt Power House			
	Date:	04/17/201	The state of the s	

i. <u>PURPOSE</u>

Define process of Suspicious Order Monitoring (SOM) for all controlled substances ordered directly by Par Trade Customers via a Purchase Order.

II. POLICY

As determined by Sales Operations with guidance from Quality Compliance ensuring we are in line with DEA requirements.

III. RESPONSIBILITY

Sales Operations/Account Services to monitor applicable Par Trade Customer Purchase Orders for any notable variations in ordering patterns.

PAR PHARMACEUTICALING. STANDARD OPERATING PROCEDURE

Title: SUSPICIOUS ORDER MONITORING (SOM)	
Department SALES OPERATIONS	S.O.P. No.: SO002,0
Supersedes: NA Effective Date:	Page: 2 of 4
APR 1-7 2012	

IV. PROCEDURE

Par's Trade customers transmit Controlled Purchase Orders via EDI and minimal Purchase Orders come in via fax/scan-email.

Weekly replenishment Purchase Orders are analyzed by Account Service Executives verses Customer provided usages.

If quantities are higher than the average transmission it is questioned.

The Buyer is contacted to review, a written request is asked as to the reason for the increase.

It is reviewed to ensure it is correct and warranted.

Seasonal changes are monitored if applicable to the product.

Monthly reports are generated by Account Services and sent to Quality Compliance for submission to the DEA on a quarterly basis; only for CII and CIII Narcotic products.

Par's top Trade Customers were asked to sign a document stating usages.

Customer Usage grids are created for each controlled drug distributed as a benchmark to monitor Customer Purchase Orders.

Customers may have a change in usage when reported or uncovered grid would then get updated to reflect accordingly.

Controlled Substance product launch

100% audit conducted for all customers purchasing product before it ships for the first time.

https://www.deadiversion.usdoj.gov/webforms/validateLogin.jsp

100% audit conducted on a quarterly basis post launch by use of above DEA site is completed for all Trade Customers DEA registrations that purchase controlled

PAR PHARMACEUTICAL INC. STANDARD OPERATING PROCEDURE

Title: SUSPICIOUS ORDE	R MONITORING (SOM)	
Department: SALES OPER	ATIONS	S.O.P. No: S0002.0
Supersedes: NA	Effective Date: APR 1.7 2012	Page: 3 of 4

substances from Par. This is to ensure we are not shipping to Trade Customers who may have a suspended license and not have communicated to PAR in a timely manner.

V. RELATED SOPs

There are no related SOPs.

VI. ATTACHMENTS

Sample of a Customer Usage Letter at Product Launch

PAR PHARMACEUTICAL, INC.

Standard Operating Procedure Revision Tracking Sheet

Title: SUSPICIOUS ORDER MONITORING (SOM)

SOP: SO002.0

Dept.: SALES OPERATIONS

Version	Supersedes	Reason for Change
SO002.0	NA	NA S
TITE -		

SOP QA026 Form No. QA065.1

Sample of Customer Usage Letter at product Launch

Attachment for SOP SO002

October 1, 2010

Ms. Renes Kenney
Vice President Sales
Par Pharmaceutical Companies, Inc.
One Ram Ridge Road
Spring Valley, NY 10977

Re: Letter of intent to purchase

Dear Ms. Kenney:

Medico Health Solutions, Inc. Intends to purchase Hydrocodone Polistirex & Chlorphoniramme Polistirex ER Oral Suspension 473 mL C-III (generic version of Tussionex Oral Suspension) from Par Pharmaceutical Companies, Inc. We understand this product is launching with limited supply and therefore would like to express our intent to purchase based on the quantities listed below.

This data represents our annual usage broken out by month to reflect the seasonality of this product and is intended to cover the purchase period October 1, 2010 through September 30, 2011.

Month"	Extended Unit
Oct 2010	280
Nov 2010	280
Dec 2010	280
Jan 2011	250
Feb 2011	275
Mar 2011	350
Apr 2011	225
May 2011	250
Jun 2011	310
Jul 2011	200
Aug 2011	225
Sep 2011	275
Total	3200

POs for our initial purchase will follow shortly. Please update me on your whility to deliver as soon as possible. Thank you for your assistance.

Sincerely,

Patricis Herzberg Sr Director Generic Drug Purchasing Medoc Health Solutions, Inc.

£1839.7

PAR PHARMACEUTICAL INC. STANDARD OPERATING PROCEDURE

Department: SALES C	S.O.P. Na: SO002.0	
Supersedes: NA	Effective Date: APR 17.2012	Page: 4 of 4

KNOWLEDGE SKILL ASSESSMENT

PLEASE CIRCLE THE CORRECT ANSWER

Par ships controlled substances on Fridays.

TRUE of FALSE

50% audit of Par's Trade Customers is conducted at launch.

TRUE o(FALSE

3. Weekly replenishment PO's are analyzed verses customer usages provided.

TRUE or FALSE

4. Usage numbers may change through the life of the product.

TRUE or FALSE

PLEASE SIGN YOUR NA	ME		DATE	
255M686 C#45725656545577 55			MONTHA	DAY/YEAR
				*
REVIEWED 8Y	<u> </u>		DAIE	DAY/YEAR
Z***	100	No. 1	(800,443.130)	Direct F1 Coron